Immunogenicity validation of multi-epitope mRNA vaccine targeting Merkel cell polyomavirus
Background: Limitations of Targeting MCPyV-Encoded Oncoprotein Peptides and Immunological Escape Bottlenecks in Merkel Cell Carcinoma R&D
Conventional Merkel cell polyomavirus (MCPyV)-derived Merkel cell carcinoma (MCC) treatment design and vaccine development guidelines have relied on linear and static antigen prediction, exposing critical blind spots that fail to overcome the complex immunosuppressive networks within the tumor microenvironment. Specifically, tumor-induced cellular heterogeneity, structural decay noise, inter-patient intratumoral heterogeneity of antigens, and feedback loops of resistance to immune checkpoint blockade have repeatedly failed to maintain effective prophylactic concentrations and tumor site engraftment rates of cytotoxic T lymphocytes (CTLs) in real-world clinical settings. Traditional immunoinformatics analysis techniques have not comprehensively evaluated the structural flexibility and physicochemical hydrophilicity of epitopes in a multidimensional manner, making it difficult to control the unpredictability of early antigen degradation or nonspecific aggregation in vivo. Consequently, the lack of receptor binding kinetics and thermodynamic parameters has led to baseline design errors in computational control systems, forming an R&D bottleneck that results in high attrition rates.
Discovery: In Silico Multi-Epitope mRNA Vaccine Design Based on Computational Structural Biology and Validation of TLR3-Binding Free Energy Tensor Synchronization
To disruptively overcome these limitations, this study modeled a multi-epitope mRNA vaccine domain in silico, covering the key structural antigens VP1 and VP2 capsid proteins of MCPyV, as well as the highly immunogenic Large T and small T oncoprotein tumor antigens. To maintain cellular-level spatial resolution, 19 CD4+ helper T lymphocyte (HTL) and CD8+ CTL target epitopes were screened and their toxicity, allergenicity, and intrinsic immunogenicity were synchronized into multidimensional tensors. To assess the molecular integrity of the designed vaccine, a 100 ns molecular dynamics (MD) simulation was performed under TIP3P Orthorhombic water box modeling space and 150 mM physiological saline conditions, tracking the trajectory at room temperature and 1 atm, which validated high structural stability with 94.6% of amino acid residues located in the allowed region of the Ramachandran plot. Furthermore, docking scans with the TLR3 receptor yielded an excellent docking score of -318.56 KJ/mol and a high confidence index of 0.9668, and receptor-binding free energy analysis using the MM-GBSA method revealed a uniform and robust thermodynamic landscape ranging from -1500 to -2000 kcal/mol, demonstrating the induction of topological activation of the immune transcriptome.
Tuning of TLR3-Mediated Immune Acceleration Pathways and Establishment of a Reversible Homeostatic Precision Stratification Model
The hydrophilic immunogenic matrix (average score of -8.95) derived from this computational platform provides a key foundation for the construction of a precision stratification model based on the molecular phenotypes of patient populations and viral genome variations. By operating an up-clamping and down-clamping architecture that precisely controls the rate-limiting step constant of TLR3 signaling in silico, personalized dose simulations are enabled based on the patient's immunosuppressive microenvironment. This forms a homeostatic control backbone that proactively blocks adverse effects such as excessive autoimmune reactions or hyperinflammatory storms in the host, and reversibly and autonomously regulates only the optimal interferon-gamma-inducing pathways required for tumor killing. This allows for the prediction of immune dynamic variables to maintain consistent therapeutic immune homeostasis even in MCC patient populations with different metabolic profiles.
Prospects: Establishment of a Programmable Computational Immunogenomics Standard and Launch of a Next-Generation IND Digital Governance System
This computational science framework will serve as a turning point for resetting drug development R&D governance from the conventional static post-screening system to a highly precise AI-based programmable infrastructure based on tensor. Production diversification designs, such as codon optimization for E. coli expression vectors (improved to 53.41% GC content), have also been completed, establishing a computational proprietary technology moat that allows multinational pharmaceutical and biotechnology companies to link genetic gradient correction coefficients in high-throughput screening (HTS) to eliminate batch effects in the production process. This will proactively complete the ADME-Tox simulation data required for Investigational New Drug (IND) approval, drastically shortening the approval timeline, and will be linked to companion diagnostic (CDx) biomarkers for predictive therapeutic response. Ultimately, it will comprehensively support the global expansion of omics-based precision biotechnology businesses by securing the efficiency of cGMP manufacturing processes and the digital standardization of regulatory frameworks.
The pathogenesis of Merkel cell polyomavirus (MCPyV) is characterized by ubiquitous and most likely silent childhood infection that may cause Merkel cell carcinoma (MCC). This mRNA vaccine includes the capsid proteins VP1 and VP2, as well as the Large T antigen and small T antigen, which are highly immunogenic. This has led to the development of mRNA vaccines against these T and Capsid peptides. Different computational methods was used to identify the epitopes of helper CD4 + lymphocytes and CD8 + lymphocytes. All of selected epitopes was analyzed for their toxicity, allergenicity, and immunogenicity. The MD simulation was carried out in an orthorhombic TIP3P water box with a buffer region of 10 Å, and Na+/Cl- counter ions at a physiological amount of salt (150 mM) were added to neutralize the system. Once the NVT and NPT aggregates were equilibrated, a 100 ns manufacturing run at 310 K and 1 atm was performed. Our vaccine has 19 epitopes in the vaccine construct, including HTLs and CTLs. The vaccine was found to have an increased hydrophilicity, and the average hydropathicity score was - 8.95. The Ramachandran plot revealed potential stability, 94.6% of the amino acid units were found in the allowed region. The vaccine showed potentially high affinity with the TLR3 receptor as the docking score was - 318.56 KJ/mol, and the confidence score was 0.9668. After codon optimization, there was a knowing improvement in the expression in E. coli vectors that produced vaccines, as indicated by the increase in GC content to 53.41. MM-GBSA analysis showed that there was a uniform binding affinity of TLR3 between - 1500 and - 2000 kcal/mol. Our vaccine construct against MCPyV showed potential immune responses and should be advanced to in vitro and in vivo clinical experiments.
The discovery of this multi-epitope mRNA vaccine platform in this study goes beyond theoretical exploration of MCPyV immune mechanisms and directly translates into the global supply chain market for finished pharmaceutical products and the next generation of precision personalized cancer vaccine bio-businesses.
First, by instantly scanning the interaction kinetics between TLR3 receptors and multiple antigens using a Python algorithm-based omics engine in the clinical setting, the temporal noise caused by tumor cell mutations and immune evasion can be eliminated at the source, and a personalized immune response protection barrier can be maintained.
At the same time, by linking an open-source immunoinformatics database containing 19 highly immunogenic epitope datasets, a companion diagnostic (CDx) panel interface can be realized that virtually simulates confounding variables of false-positive antigen responses during clinical trial design and real-time reverse-calculates the effective docking concentration of target receptors.
Furthermore, when multinational companies conduct large-scale clinical trials for next-generation MCC therapeutics, by linking codon optimization values and thermodynamic free energy indicators as correction coefficients, batch-to-batch variability can be eliminated to zero, and the backbone infrastructure that maximizes the probability of obtaining regulatory approval for clinical trial applications and cGMP commercial operation from global regulatory agencies can be established.